Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,769 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06873269Recruiting
Holmium-166 radiation therapy for liver cancer
This trial tests a radiation treatment for liver cancer that cannot be removed with surgery or ablation. Tiny beads containing Holmium-166 are injected into the liver's blood supply to target the tumor directly.
BrusselsAges 18 years+ - NCT07308106RecruitingPhase 2
Testing SKB571 for MET-mutated advanced lung cancer
This trial tests a new drug called SKB571 for people with advanced lung cancer that has a specific change in the MET gene. The goal is to see if the drug can shrink tumors or stop them from growing.
ShanghaiAges 18–75 - NCT07309185RecruitingPhase 2
Adebrelimab, famitinib, and irinotecan for advanced stomach cancer
This trial tests a combination of three drugs (adebrelimab, famitinib, and irinotecan) for people with advanced stomach or gastroesophageal junction cancer that got worse after first-line treatment. It may offer a new option if you have already tried standard therapy.
Jinan, ShandongAges 18–75 - NCT07302347RecruitingPhase 1/Phase 2
Study of pembrolizumab for different cancers in Japan
This trial tests a drug called pembrolizumab (Keytruda) to see if it helps people with several types of cancer, including relapsed or refractory lymphoma, melanoma, MSI-high or TMB-high solid tumors, and Merkel cell carcinoma. The goal is to understand if this immunotherapy can shrink or control the cancer.
Nagoya, Aichi-kenAges 6 months+ - NCT07291037RecruitingPhase 3
Comparing a new drug to standard chemo for advanced lung cancer
This trial tests a new drug called datopotamab deruxtecan against a standard chemotherapy (docetaxel) for people with a certain type of advanced lung cancer (non-squamous non-small cell lung cancer) that has already been treated. The new drug targets a protein called TROP2 found on cancer cells, which may help slow or stop the cancer's growth.
Chandler, ArizonaAges 18 years+ - NCT06823427RecruitingPhase 2
9MW2821 with or without immunotherapy for advanced urothelial cancer
This trial tests a combination of an investigational drug (9MW2821) with an immunotherapy (toripalimab) against 9MW2821 alone for people with advanced urothelial cancer who have not yet received any systemic treatment. The goal is to see if the combination works better than the single drug.
Changsha, HunanAges 18–80 - NCT07276373RecruitingPhase 1/Phase 2
Nenocorilant with nivolumab for advanced solid tumors
This trial tests a new drug called nenocorilant combined with nivolumab (an immunotherapy) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if this combination is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07272512RecruitingPhase 4
Surufatinib for advanced neuroendocrine tumors
This trial tests the drug surufatinib in people with advanced neuroendocrine tumors. It is a real-world study, meaning it looks at how the drug works in everyday practice, and may help control tumor growth.
ShanghaiAges 18 years+ - NCT06840067Recruiting
Carbon ion radiotherapy for pancreatic cancer
This trial tests a new type of radiation called carbon ion therapy for people with advanced pancreatic cancer (stages III–IV) that has spread or can't be removed by surgery. It's combined with standard chemotherapy (gemcitabine plus nituzumab) to see if it can help shrink tumors and improve outcomes.
Wuwei, GansuAges 18–80 - NCT07264816RecruitingPhase 2
Study of BL-M07D1 and Pembrolizumab for HER2+ Lung Cancer
This study tests a new drug combination, BL-M07D1 plus pembrolizumab (an immunotherapy), for people with a certain type of advanced lung cancer that has high levels of HER2 protein. The goal is to see if the combination is safe and effective for people who have not been treated with HER2-targeting drugs before.
Wuhan, HubeiAges 18–75 - NCT07261631RecruitingPhase 1
A study of a new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
Princeton, New JerseyAges 18 years+ - NCT07249775Recruiting
Study of new drug FID-022 for pancreatic cancer
This trial tests a new study drug called FID-022 for people with pancreatic cancer. It is a first-in-human study, meaning it is the first time this drug is being tested in people, and researchers want to see if it is safe and how it works.
Tampa, FloridaAges 18 years+ - NCT07250477RecruitingPhase 2
Guided immunotherapy for advanced lung cancer
This trial tests whether using a blood test to guide treatment can improve outcomes for people with advanced non-small cell lung cancer who are starting immunotherapy for the first time. Participants will receive standard immunotherapy tailored to their individual risk profile.
Chico, CaliforniaAges 18 years+ - NCT07244705RecruitingPhase 1/Phase 2
Study of ABT-301 plus tislelizumab and bevacizumab for advanced colorectal cancer
This trial tests a new drug combination (ABT-301, tislelizumab, and bevacizumab) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination can help shrink tumors or slow the disease.
Liverpool, New South WalesAges 18 years+ - NCT07247110RecruitingPhase 1
Study of MK-4716 for people with certain solid tumors
This trial tests a new drug, MK-4716, alone or with cetuximab or pembrolizumab, for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink tumors or slow their growth.
New Brunswick, New JerseyAges 18 years+ - NCT07244835RecruitingPhase 1
A study of DEG6498 for advanced solid tumors
This trial tests a new drug, DEG6498, for people with advanced solid tumors that have not responded to other treatments. It may be an option if your cancer has a BRAF mutation or is a type of liver cancer called HCC.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06620848RecruitingPhase 2
A trial of HRS-4642 alone or with adebrelimab for advanced bile duct cancer
This trial tests a new drug, HRS-4642, either by itself or combined with another drug called adebrelimab, for people whose advanced bile duct cancer has come back or gotten worse after standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07231068RecruitingPhase 1/Phase 2
Dositinib tablets for advanced lung cancer with EGFR mutation
This trial tests a new targeted therapy, Dositinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to earlier EGFR-targeted drugs. It aims to find the best dose and see how well it shrinks tumors.
BeijingAges 18–75 - NCT07232849RecruitingPhase 2
New drug combo for advanced lung cancer
This trial tests a new drug, HRS-4508, given with other cancer treatments for people with advanced non-small cell lung cancer whose previous treatments have failed. The goal is to see if this combination can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07235202RecruitingPhase 1/Phase 2
MR001 plus chemo for advanced pancreatic cancer after first treatment
This trial tests a new drug, MR001, combined with chemotherapy for people whose pancreatic cancer has spread and no longer responds to their first treatment. It aims to see if this combination can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07231120RecruitingPhase 1
Testing SXRN injection for cancer-related weight loss
This trial tests a new injection called SXRN for people with advanced cancer who have lost weight and appetite (cancer cachexia). The goal is to see if it is safe and might help improve weight and appetite.
Beijing, Beijing MunicipalityAges 18–75 - NCT07235566RecruitingPhase 2
MRG003 plus pucotenlimab for advanced thyroid cancer (ATC/PDTC)
This trial tests two drugs together: MRG003 (a targeted therapy that delivers chemo directly to EGFR-positive cancer cells) and pucotenlimab (an immunotherapy that helps your immune system attack the cancer). It is for people with a rare and aggressive thyroid cancer (ATC or PDTC) whose tumors have the EGFR protein and have grown despite previous treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06797297RecruitingPhase 2
Study of IBI363 vs pembrolizumab for advanced mucosal or acral melanoma
This trial tests a new drug, IBI363, compared to the standard drug pembrolizumab (Keytruda) for people with advanced mucosal or acral melanoma who have not had treatment before. It aims to see if IBI363 works better or as well as the usual treatment.
Hefei, AnhuiAges 18 years+ - NCT07224425RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug called BI 3810944 for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the drug is safe and helps shrink tumors.
Louisville, KentuckyAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,769 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.